- The FDA has appoved BioCryst Pharmaceuticals' (NASDAQ:BCRX) oral, once-daily Orladeyo (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.
- HAE is a disorder characterized by recurrent episodes of severe swelling (angioedema). The most common areas of the body to develop swelling are the limbs, face, intestinal tract, and airway.
FDA OKs BioCryst Pharma's Orladeyo to prevent attacks in hereditary angioedema
Recommended For You
About BCRX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
BCRX | - | - |
BioCryst Pharmaceuticals, Inc. |